PDF(Pubmed)
Abstract：
Utrophin (UTRN), known as a tumor suppressor, potentially regulates tumor development and the immune microenvironment. However, its impact on breast cancer\'s development and treatment remains unstudied. We conducted a thorough examination of UTRN using both bioinformatic and in vitro experiments in this study. We discovered UTRN expression decreased in breast cancer compared to standard samples. High UTRN expression correlated with better prognosis. Drug sensitivity tests and RT-qPCR assays revealed UTRN\'s pivotal role in tamoxifen resistance. Furthermore, the Kruskal-Wallis rank test indicated UTRN\'s potential as a valuable diagnostic biomarker for breast cancer and its utility in detecting T stage of breast cancer. Additionally, our results demonstrated UTRN\'s close association with immune cells, inhibitors, stimulators, receptors, and chemokines in breast cancer (BRCA). This research provides a novel perspective on UTRN\'s role in breast cancer\'s prognostic and therapeutic value. Low UTRN expression may contribute to tamoxifen resistance and a poor prognosis. Specifically, UTRN can improve clinical decision-making and raise the diagnosis accuracy of breast cancer.
摘要：
Utrophin(UTRN),被称为肿瘤抑制剂，潜在的调节肿瘤的发展和免疫微环境。然而,它对乳腺癌的发展和治疗的影响仍未被研究。在这项研究中，我们使用生物信息学和体外实验对UTRN进行了全面检查。我们发现与标准样品相比，乳腺癌中的UTRN表达降低。UTRN高表达与较好的预后相关。药物敏感性试验和RT-qPCR检测揭示了UTRN在他莫昔芬耐药中的关键作用。此外，Kruskal-Wallis秩检验表明UTRN作为乳腺癌有价值的诊断生物标志物的潜力及其在检测乳腺癌T分期中的应用价值.此外,我们的结果表明UTRN与免疫细胞密切相关，抑制剂，刺激器,受体,乳腺癌中的趋化因子（BRCA）。本研究为UTRN在乳腺癌预后和治疗中的作用提供了新的视角。低UTRN表达可能导致他莫昔芬耐药和预后不良。具体来说,UTRN可以改善临床决策，提高乳腺癌诊断的准确性。
